Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
dc.authorwosid | Betancourt, Rafael/JCP-1922-2023 | |
dc.authorwosid | liu, liu/JEO-6900-2023 | |
dc.authorwosid | cong, z/KCF-0053-2024 | |
dc.contributor.author | Tolaney, Sara M. | |
dc.contributor.author | Cicin, Irfan | |
dc.contributor.author | Betancourt, Rafael | |
dc.contributor.author | Chan, Arlene | |
dc.contributor.author | Kaen, Diego | |
dc.contributor.author | Kaufman, Peter A. | |
dc.contributor.author | Delaloge, Suzette | |
dc.date.accessioned | 2024-06-12T11:23:58Z | |
dc.date.available | 2024-06-12T11:23:58Z | |
dc.date.issued | 2020 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description | Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 29-31, 2020 -- ELECTR NETWORK | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
dc.description.sponsorship | Sanofi | en_US |
dc.description.sponsorship | Sanofi | en_US |
dc.identifier.issn | 0732-183X | |
dc.identifier.issn | 1527-7755 | |
dc.identifier.issue | 15 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/26746 | |
dc.identifier.volume | 38 | en_US |
dc.identifier.wos | WOS:000560368309024 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.ispartof | Journal Of Clinical Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies. | en_US |
dc.type | Conference Object | en_US |